Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Presbyopia: A Broadening Market Accommodates New Medtech Innovations

This article was originally published in Start Up

Executive Summary

The arrival of a new generation of intraocular lenses and corneal inlays – designed to offer clearer, improved vision without the need for reading glasses – is expected to spur growth in the presbyopia market.

You may also be interested in...



All Eyes On Ophthalmic Devices Market

In the ophthalmic device sector, intraocular lens surgery is expanding way beyond the cataract market with paradigm shifting technology. The vast presbyopia market now has an FDA-approved "corneal inlay" option, micro invasive glaucoma surgery has created an entirely new device segment, and corneal cross-linking has the potential to transcend its role as an effective treatment for a corneal disease to possibly being the next big thing in the non-surgical treatment of refractive errors.

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.

Alarming Rise Of Diabetes in Several US States, Study Shows

A study of diabetes rates across the US over four years reveals significant increases in the disease in many states. Tobias Oerum, diabetes advocate and cofounder of the company that conducted the study, discussed the data and some of the factors contributing to this troubling trend with Medtech Insight.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT038050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel